The 'Dispatched' Podcast

A very busy week with mostly relief for patients accessing PBS-funded multiple sclerosis medicines, but what does it really mean, and what is the opportunity? Reports and their questionable citations....

17 Heinä 1h 3min

The MS medicines controversy continues. Why wouldn’t the minister just deal with it and make it go away? It may not be that easy. Why any resolution will probably deal with symptoms rather than the ca...

10 Heinä 53min

A small player with no market share and no real prospect of gaining any agreed to an almost 50 per cent price reduction to secure reimbursement. Who would have thought the market leaders would respond...

3 Heinä 1h 12min

Congratulations to one of Australia's leading health journalists on a highly effective series of stories and commentaries that reveal the true extent of this country's challenge and the problems patie...

26 Kesä 1h 2min

The emerging impact of China's use of international reference pricing might pose a significant risk to access to medicines in Australia. The critical importance of detail and getting the basics right ...

19 Kesä 59min

Why long-term thinking and planning are the key to success. What is the ten-year goal, and how does a new agreement progress that? Plan for policy and government engagement like it's a product launch....

14 Kesä 50min

Where did these industry agreements come from, and why? In the first episode of a two-part special, we discuss the genesis of the Australian government's agreements with the industry, based on persona...

5 Kesä 1h 15min

Powerful patient stories stand in contrast to a decision-making framework that explicitly dehumanises their lived experience. The need for 'decency and compassion'. Week one of Senate Estimates, the c...

28 Touko 1h 3min